banner

Posts tagged as: GlaxoSmithKline herpes vaccine back to homepage

Glaxo Genital Herpes Vaccine Flops but Genocea a Buy in Vaccine Space Glaxo Genital Herpes Vaccine Flops but Genocea a Buy in Vaccine Space(0)

By Rex Graham

A Glaxo Smith Kline (GSK) genital herpes vaccine recently flopped in a large clinical trial, but “next generation” genital herpes vaccines by Genocea Biosciences, Agenus, Inc. (AGEN), Vical, Inc. (VICL), and Sanofi Pasteur (SNY) offer new hope for an effective vaccine treatment.

A Yale University study published in the Nov. 15, 2012, issue of Nature described a simple technique to “pull” memory immune cells, a few days after genital herpes vaccination shots, directly Read More

OTCBB News

Electronic Control Security Lands Prime Government Contract Electronic Control Security Lands Prime Government Contract(0)
Balqon Lithium Battery System Installed in Hybrid Yacht Balqon Lithium Battery System Installed in Hybrid Yacht(0)
Ecosphere Delivers Two More Ozonix Water Treatment Units to Hydrozonix Ecosphere Delivers Two More Ozonix Water Treatment Units to Hydrozonix(0)
ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer ALR Technologies Names Former Pfizer Exec as Chief Commercial Officer(0)
Cellceutix Enters $10 Million Share Purchase Agreement, Shares Jump Cellceutix Enters $10 Million Share Purchase Agreement, Shares Jump(0)
Drinks Americas Signs Sales Agreement for Marigold Craft Beer Drinks Americas Signs Sales Agreement for Marigold Craft Beer(0)
read more


Stay Informed

Receive the OTCS Newsletter *




*

* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Gateways

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories
Disclaimer/Disclosure
© 2011 Viper Enterprises, LLC. All rights reserved.